Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Crossover, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors, in Adults with Hypertension and Chronic Kidney Disease with Albuminuria

Next Previous
Trial Profile

A Randomized, Crossover, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors, in Adults with Hypertension and Chronic Kidney Disease with Albuminuria

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorundrostat (Primary) ; Dapagliflozin
  • Indications Hypertension; Resistant hypertension
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms Explore-CKD
  • Sponsors Mineralys Therapeutics

Most Recent Events

  • 17 Jun 2025 Primary endpoint (Placebo-adjusted change from baseline in automated office blood pressure (AOBP) systolic blood pressure (SBP) at Week 4) has been met.
  • 17 Jun 2025 Results presented in the Mineralys Therapeutics Media Release
  • 21 Feb 2025 Planned primary completion date changed from 1 Feb 2025 to 1 May 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top